Search Results

Verge Genomics and Ferrer have announced a strategic collaboration to co-develop VRG50635, Verge’s lead drug candidate, for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis, in Europe, Central and South America, Southeast Asia, and Japan.

Marking a milestone in pharmaceutical innovation and excellence, Dr. Ferrer BioPharma has been honored with a prestigious award at the renowned CPHI Pharmapack 2024, which took place at the Paris Expo, Porte de Versailles.

Genomma Lab Internacional, S.A.B. de C.V., announced its results for the first quarter of 2024.

Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of business on June 21, 2024.

Leading pharmaceutical research and development company Dr. Ferrer Biopharma proudly announces its participation in the highly anticipated European Respiratory Society (ERS) Congress 2023, scheduled in Milan, Italy, from September 9th to 13th.

The international pharmaceutical company Ferrer has announced the extension of its phase III clinical trial ADORE, with FNP122 in amyotrophic lateral sclerosis.

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the fourth quarter and full year ended December 31, 2023.

The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research and Ferrer has been included by the World Health Organization in its List of Essential Medicines.

Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange declaring a cash dividend of $0.196080 Mexican pesos per share on its common stock representing a total amount of $200,001,600.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of business on March 25, 2024.